GSK in Canada
GSK has a history in Canada that dates back to 1902
We currently employ approximately 1,700 full time employees across the country, providing a salary injection of $287 million into the Canadian economy. We have two divisional headquarters in Mississauga, Ontario and Montréal, Quebec, and an administrative office in Quebec City.
Manufacturing
Our manufacturing facility is located in:
Ste-Foy - Quebec
The Ste-Foy vaccine manufacturing site currently produces a majority share of Canada’s seasonal influenza vaccine and is responsible for the domestic supply of the country’s pandemic influenza vaccine requirements.
Research & Development
We have invested more than $2 billion since 2001 in Canadian pharmaceutical and vaccines Research & Development (R&D), with 89 million in 2021 alone. In 2021, we invested over $23 million into 45 active clinical trials across Canada involving 4,000 active subjects.
Community Investment
-
Over $690,000
Invested in grants and donations to community groups by GSK in Canada in 2021
-
Over $3,000,000
Contributed over the last 20 years to support the hospice palliative care movement in Canada. In 2021 only, we contributed $125,000 to help ensure every Canadian has access to quality hospice palliative care.
-
11,000+
Emergency backpacks have been assembled since 2016 by GSK and Save the Children and have been used as part of emergency preparedness and resiliency programming with Indigenous children, families and communities in Alberta, Saskatchewan, Manitoba, Ontario, and Quebec.
Environmental Sustainability
In October 2018, GSK launched a Centralized Waste program involving the removal of individual waste containers from offices to promote environmental consciousness and reduce our contribution to landfills.
In November 2020, GSK announced ambitious new environmental sustainability goals in both climate and nature, aiming to have a net zero impact on climate and a net positive impact on nature by 2030.
COVID-19
Our Response
- We are collaborating with companies and research groups across the world—working on COVID-19 vaccine candidates through the use of our pandemic adjuvant technology.
- We do not expect to profit from COVID-19 vaccines during the pandemic phase, and will invest any short-term profit in coronavirus related research and long-term pandemic preparedness.
- GSK Canada has contributed over $750,000 in corporate grants in support of COVID-19 relief efforts
Ways of Working
GSK is committed to building transparency in our operations because it enhances trust and value for patients and our healthcare system.
Since 2017, GSK has been among ten leading pharmaceutical companies in Canada that have voluntarily disclosed aggregate payments to healthcare providers (HCPs) and healthcare organizations. Starting in 2020 and onwards, we are disclosing individual level payments made annually to HCPs.
